Resveratrol potential fires interest in longevity drugs

Interest in longevity drugs continues to grow as new research points to the tonic effects of resveratrol. The New York Times notes that some scientists have become so enamored by the potential of the ingredient they have begun to take it in pill form. And the implications could be huge for any developer like Sirtris.

"The upside is so huge that if we are right, the company that dominates the sirtuin space could dominate the pharmaceutical industry and change medicine," said Dr. David Sinclair of the Harvard Medical School, a co-founder of the company.

- read the article in The New York Times

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.